Baricitinib Development as a Lupus Treatment Discontinued
January 28, 2022
The Lupus Research Alliance is disappointed that the Phase 3 development program of OLUMIANT® (baricitinib) as a...
baricitinib
Promise of Additional Lupus Therapies Highlighted at ACR 2021 Annual Meeting
November 9, 2021
Results of clinical trials testing many existing and potential lupus treatments were highlighted at the American College...
Promising News from Major Medical Meeting, EULAR
Updated June 5, 2020
One of the largest meetings for rheumatologists went virtual this year to enable scientists from around...
Lupus Research Alliance Encouraged by Lilly Looking at Potential Lupus Drug for COVID-19
April 23, 2020
The Lupus Research Alliance is pleased to share that Eli Lilly and Company entered into an agreement...
Updates in Lupus Clinical Research from the LUPUS 2019 Meeting
April 11, 2019
The Lupus Research Alliance is pleased to share the results from four clinical trials presented at LUPUS...
Stelara® and Olumiant® Considered Promising by Lupus Expert
February 19, 2019
In Healio Rheumatology, Dr. Gregg Silverman, professor of medicine and pathology at NYU School of Medicine, provided...
Lupus Research Alliance Applauds FDA’s Fast Track Designation to Develop Baricitinib for Lupus
NEW YORK, NY. December 14. The Lupus Research Alliance is pleased to share good news about a potential new...
ACR|ARHP News on Potential New Lupus Treatments
October 25, 2018
The Lupus Research Alliance was on the ground at the American College of Rheumatology 2018 meeting to...
Baricitinib Shows Positive Results for SLE in Phase 2 Study
June 19, 2018
Once-daily oral baricitinib 4 mg was associated with significant clinical improvements compared with placebo in patients with...